Friday, February 15, 2019 4:45:14 PM
Some occur after 1 dose. Some occur years later.
Nobody yet knows just how effective the ICI's can be in producing adverse outcomes.
Documented toxicities include (but are not limited to):-
Rash
Pruritis
Vitiligo
Immunobullous skin lesions akin to dermatitis herpetiformis or bullous pemphigoid
Keratinocyte alteration—Grover’s disease [27]/acantholytic dyskeratosis
Immune-reaction mediated by alteration of melanocytes (regression of nevi, prurigo nodularis, tumoural melanosis and vitiligo).
Thyroid dysfunction
Hyperthyroidism
Hypothyroidism
Hypophysitis
Diabetes mellitus
De novo diabetes
Hepatitis
Gastrointestinal toxicity
Diarrhoea
Colitis
Colon perforation
Enterocolitis
Dysphagia
Epigastric pain
Oesophageal ulcerations,
Gastritis,
Duodenitis
Lymphocytic colitis
Pancreatitis
Small bowel enteritis
Pneumonitis
Grade 3 to 4 cough
Grade 3 to 4 dyspnoea
Neurological toxicity
Polyneuropathy
Facial nerve palsy,
Demyelination
Myasthenia gravis,
Guillain Barré syndrome
Posterior reversible leukoencephalopathy
Transverse myelitis
Enteric neuropathy
Encephalitis
Aseptic meningitis
Cardiac toxicity
Myocarditis
Pericarditis
Arrhythmias,
Cardiomyopathy
Impaired ventricular function
Rheumatological toxicity (as you mentioned)
Myalgia
Arthralgia
Vasculitis
Polymyositis,
Myositis
Temporal arteritis
Renal toxicity
Grade 3 to 4 nephritis
Acute kidney injury
Acute tubulo-interstitial nephritis with lymphocytic infiltration
Severe antineutrophil cytoplasmic antibody-associated rapid progressive glomerulonephritis
Ocular toxicities
Peripheral ulcerative keratitis
Uveitis
Vogt–Koyanagi–Harada syndrome
Thyroid-associated orbitopathy and idiopathic orbital inflammation (sceritis, myositis, neuritis, dacryadenitis)
Retinal and choroidal disease (choroidal neovascularisation and melanoma-associated retinopathy)
Haematological toxicities
Lethal aplastic anaemia
Autoimmune haemolytic anaemia
Immune thrombocytopenic purpura
New effects are being discovered all the time.
Such as hyperprogression.
There have been a few isolated reports of actual treatment benefit to a minority.
Though these benefits are normally shortlived.
And I have not been able to verify these reports.
The list of toxicities is not meant to be exhaustive, as new ones are being discovered all the time.
A very versatile treatment..
Strangely, some well-informed patients with advanced disease who wish to extend their survival, opt for best palliative care instead of ICI treatment.
"Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines"
https://www.esmo.org/Guidelines/Supportive-and-Palliative-Care/Management-of-Toxicities-from-Immunotherapy
Recent NWBO News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM